Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 3, May-June, p. 449–455

doi: 10.17219/acem/35639

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Adiponectin and Cardiac Hypertrophy in Acromegaly

Sabriye Gurbulak1,B, Fulya Akin2,A,C,D,E, Emrah Yerlikaya3,D, Guzin F. Yaylali2,C,E, Senay Topsakal2,B, Halil Tanriverdi4,B, Beyza Akdag5,C, Bunyamin Kaptanoglu6,B

1 Department of Internal Medicine, Pamukkale University, Turkey

2 Department of Endocrinology, Pamukkale University, Turkey

3 Department of Endocrinology, Denizli State Hospital, Turkey

4 Department of Cardiology, Pamukkale University, Turkey

5 Department of Biostatistics, Pamukkale University, Turkey

6 Department of Biochemistry, Pamukkale University, Turkey


Background. Adiponectin is an adipocytes-derived hormone which has been shown to possess insulin-sensitizing, antiatherogenic, and anti-inflammatory properties. In acromegaly, the data on adiponectin is contradictory. The relationship between adiponectin levels and cardiac parameters has not been studied.
Objectives. The aim of this study was to find out how adiponectin levels were affected in acromegalic patients and the relationship between adiponectin levels and cardiac parameters.
Material and Methods. We included 30 subjects (15 male, 15 female), diagnosed with acromegaly and 30 healthy (10 male, 20 female) subjects. Serum glucose, insulin, GH, IGF-1 and adiponectin levels were obtained and the insulin resistance of the subjects was calculated. Echocardiographic studies of the subjects were performed.
Results. We determined that adiponectin levels were significantly higher in the acromegalic group than the control group. In the acromegalic group, there was no statistically significant relation between serum adiponectin and growth hormone (GH), or insulin-like growth factor-1 (IGF-1) levels (p = 0.3, p = 0.1). We demonstrated that cardiac function and structure are affected by acromegaly. IVST, PWT, LVMI, E/A ratio, DT, ET, IVRT, VPR, and LVESV values were increased and the results were statistically significant. In the acromegalic group, adiponectin levels were positively related with left ventricle mass index (LVMI) but this correlation was found to be statistically weak (p = 0.03). In our study, there was a positive correlation between VAI and LVM. We also could not find any correlation between VAI and adiponectin levels.
Conclusion. Although insulin resistance and high insulin levels occur in active acromegaly patients, adiponectin levels were higher in our study as a consequence of GH lowering therapies. Our study showed that adiponectin levels may be an indicator of the cardiac involvement acromegaly. However, the usage of serum adiponectin levels in acromegalic patients as an indicator of cardiac involvement should be supported with other, wide, multi-centered studies.

Key words

acromegaly, insulin resistance, cardiac hypertrophy, echocardiography, adiponectin

References (38)

  1. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagarentani H: Diet induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8, 731–737.
  2. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki KM: Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278, 2461–2468.
  3. Ouchi Y, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H: Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF B signaling through cAMP dependent pathway. Circulation 2000, 102, 1296–1301.
  4. Nuria Sucunza M, Borahona J, Resmini E, Fernandez-Real J, Ricard W, Farrerons J: A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 2009, 94, 3889–3896.
  5. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscl Throm Vas 2004, 24, 29–33.
  6. Xu A, Yin S, Wong LC, Chan KW, Lam KSL: Adiponectin ameliorates dyslipidemia induced by the HIV protease inhibitor ritonavir in mice. Endocrinology 2004, 145, 487–494.
  7. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscl Throm Vas 2003, 23, 85–89.
  8. Fayyaz I, Ahmed MZ, Shah SI, Mehmood S, Akram S, Ghani M: Serum adiponectin levels in patients with coronary artery disease. J Ayub Med Coll Abbottabad 2009, 21, 90–92.
  9. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291, 1730–1737.
  10. Chan AYM, Soltys CLM, Young ME, Proud CG, Dyck JRB: Activation of MP-activated protein kinase inhibits protein synthesis associated with hypertrophy in cardiac myocytes. J Biol Chem 2004, 279, 32771–32779.
  11. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Satp K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K: Adiponectin-mediated modulation of hypertrophic signals in the heart. Nature 2004, 10, 1384–1389.
  12. Duda MK, O’Shea KM, Lei B, Barrows BR, Azimzadeh AM, McElfresh TE, Hoit BD, Kop BD, Stanley WC: Dietary supplementation with ω-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res 2007, 76, 303–310.
  13. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM: Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 2004, 13, 236–242.
  14. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112, 1756–1762.
  15. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y: Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006, 92, 1420–1424.
  16. Jawiarczyk-Przybylowska A, Bolanowski M: The role of orexin A in metabolic disturbances in patients with acromegaly. Endokrynol Pol 2012, 63,463–469.
  17. Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A: Acromegaly and the cardiovascular system. Neuroendocrinology 2006, 83, 211–217.
  18. Silha JV, Krsek M, Hanna V, Marek J, Jezkova J, Weiss V, Murphy LJ: Perturbations in adiponectin, leptin and resistin levels in acromegaly: Lack of correlation with insulin resistance. Clin Endocrinol (Oxf) 2003, 58, 736–742.
  19. Fukuda I, Hizuka N, Ishikawa Y, Itoh E, Yasumoto K, Murakami Y, Sata A, Tsukada J, Kurimoto M, Okubo Y, Takano K: Serum adiponectin levels in adult growth hormone deficiency and acromegaly. Growth Horm IGF Res 2004, 14, 449–454.
  20. Ronchi CL, Corbetta S, Cappiello V, Morpurgo PS, Giavoli C, Beck-Peccoz P, Arosio M, Spada A: Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients. Eur J Endocrinol 2004, 150, 663–669.
  21. Olarescu NC, Ueland T, Godang K, Lindberg-Larsen R, Jorgensen JO, Bollerslev J: Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities. Eur J Endocrinol 2013, 170, 39–48.
  22. Lam KS, Xu A, Tan KC, Wong LC, Tiu SC, Tam S: Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J Clin Endocrinol Metab 2004, 89, 5448–5453.
  23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412–419.
  24. Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo C: Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J Clin Endocrinol Metab 2012, 97, 2907–2915.
  25. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N: Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986, 57, 450–458.
  26. Colao A, Marzullo P, Di Somma C, Lombardi G: Growth hormone and the heart. Clin Endocrinol (Oxf) 2001, 54, 137–154.
  27. Lie JT, Grossman SJ: Pathology of the heart in acromegaly: Anatomic findings in 27 autopsied patients. American Heart J 1980, 100, 41–52.
  28. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G: High prevalence of cardiac valve disease in acromegaly: An observational analytical prospective case-control study. J Clin Endocrinol Metab 2003, 88, 3196–3201.
  29. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ: Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004, 89, 71–75.
  30. Lopez-Velasco R, Escobar-Morreale HF, Vega B: Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 1997, 82, 1047–1053.
  31. Fazio S, Cittadini A, Biondi B: Cardiovascular effects of short-term growth hormone hypersecretion. J Clin Endocrinol Metab 2000, 85, 179–182.
  32. Mitsuhashi H, Yatsuya H, Tamakoshi K, Matsushita K, Otsuka R, Wada K: Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertension 2007, 49, 1448–1454.
  33. Top C, Sahan B, OndeME: The relationship between left ventricular mass index and insulin sensitivity, postprandial glycaemia, and fasting serum triglyceride and adiponectin levels in patients with type 2 diabetes. J Int Med Res 2007, 35, 909–916.
  34. Von Haehling S, Doehner W, Anker SD: Nutrition, metabolism and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 2007, 73, 298–309.
  35. Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K: Pioglitazone improved left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005, 8, 949–957.
  36. O’Sullivan AJ, Kelly JJ, Hoffman D, Freund J, Ho KK: Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab 1994, 78, 381–386.
  37. Tan KCB, Tso AWK, Lam KSL: Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 2001, 54, 31–35.
  38. Hanley AJ, Connelly PW, Harris SB, Zinman B: Adiponectin in a native Canadian population experiencing rapid epidemiological transition. Diabetes Care 2003, 26, 3219–3225.